New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci

► A new recombinant 30-valent M protein-based group A streptococcal vaccine. ► Vaccine design based on current epidemiology of pharyngeal and invasive infections. ► Bactericidal antibodies evoked against all vaccine serotypes of streptococci. ► Vaccine antisera were bactericidal against a number of non-vaccine serotypes.